{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:53:32Z","timestamp":1788951212334,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1124\/dmd.118.082073","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T16:10:17Z","timestamp":1528387817000},"page":"1157-1168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["S-Enantiomer of 19-Hydroxyeicosatetraenoic Acid Preferentially Protects Against Angiotensin II-Induced Cardiac Hypertrophy"],"prefix":"10.1016","volume":"46","author":[{"given":"Sherif M.","family":"Shoieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman O.S.","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.082073_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvp241","article-title":"Interleukin 8 and cardiovascular disease","volume":"84","author":"Apostolakis","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1124\/dmd.118.082073_bib2","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1194\/jlr.M800358-JLR200","article-title":"Strong activation of cyclooxygenase I and II catalytic activity by dietary bioflavonoids","volume":"49","author":"Bai","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.118.082073_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-2275(20)37440-X","article-title":"High polyunsaturated fatty acid, thromboxane A2, and alpha-fetoprotein concentrations at the human feto-maternal interface","volume":"38","author":"Benassayag","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.118.082073_bib4","doi-asserted-by":"crossref","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, De Ferranti SD, Floyd J, Fornage M, Gillespie C et al. (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in Circulation (2017) 135:e646; 136:e196]. Circulation 135:e146\u2013e603","DOI":"10.1161\/CIR.0000000000000491"},{"key":"10.1124\/dmd.118.082073_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.082073_bib6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1067\/mhj.2000.111112","article-title":"Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension","volume":"140","author":"Brown","year":"2000","journal-title":"Am Heart J"},{"key":"10.1124\/dmd.118.082073_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138920009787522188","article-title":"Stereoselectivity in drug metabolism: molecular mechanisms and analytical methods","volume":"10","author":"Campo","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.118.082073_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.prostaglandins.2016.07.009","article-title":"An insight into the role of arachidonic acid derived lipid mediators in virus associated pathogenesis and malignancies","volume":"126","author":"Chandrasekharan","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/dmd.118.082073_bib9","doi-asserted-by":"crossref","first-page":"H1018","DOI":"10.1152\/ajpheart.01172.2007","article-title":"20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling","volume":"294","author":"Cheng","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/dmd.118.082073_bib10","doi-asserted-by":"crossref","first-page":"e42297","DOI":"10.1371\/journal.pone.0042297","article-title":"Distinct cardiac transcriptional profiles defining pregnancy and exercise","volume":"7","author":"Chung","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/dmd.118.082073_bib11","doi-asserted-by":"crossref","first-page":"H517","DOI":"10.1152\/ajpheart.00953.2005","article-title":"Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature","volume":"291","author":"Dhanasekaran","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/dmd.118.082073_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jchromb.2013.08.008","article-title":"UHPLC-MS\/MS analysis of arachidonic acid and 10 of its major cytochrome P450 metabolites as free acids in rat livers: effects of hepatic ischemia","volume":"964","author":"Edpuganti","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.082073_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.taap.2015.10.003","article-title":"19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy","volume":"289","author":"Elkhatali","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.118.082073_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FJC.0000000000000494","article-title":"Inhibition of mid-chain HETEs protects against angiotensin II-induced cardiac hypertrophy","volume":"70","author":"Elkhatali","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/dmd.118.082073_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/1389200211314060007","article-title":"20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases","volume":"14","author":"Elshenawy","year":"2013","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.118.082073_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9010009","article-title":"Clinical implications of 20-hydroxyeicosatetraenoic acid in the kidney, liver, lung and brain: an emerging therapeutic target","volume":"9","author":"Elshenawy","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.118.082073_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bcp.2013.11.015","article-title":"Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy","volume":"87","author":"El-Sherbeni","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.082073_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/acs.molpharmaceut.5b00873","article-title":"Repurposing resveratrol and fluconazole to modulate human cytochrome P450-mediated arachidonic acid metabolism","volume":"13","author":"El-Sherbeni","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.118.082073_bib20","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1073\/pnas.72.12.5130","article-title":"Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis","volume":"72","author":"Hammarstr\u00f6m","year":"1975","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.118.082073_bib21","unstructured":"Heart and Stroke Foundation (2016) 2016 Report on the Health of Canadians. Ottawa, Canada."},{"key":"10.1124\/dmd.118.082073_bib22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2133\/dmpk.20.478","article-title":"Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs","volume":"20","author":"Imaoka","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.082073_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/HYPERTENSIONAHA.110.154518","article-title":"Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology","volume":"56","author":"Jennings","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.082073_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbapap.2010.09.009","article-title":"Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids","volume":"1814","author":"Konkel","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.118.082073_bib25","doi-asserted-by":"crossref","first-page":"H613","DOI":"10.1152\/ajpheart.00144.2010","article-title":"Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli","volume":"299","author":"Lamon","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/dmd.118.082073_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2017.03.007","article-title":"Potential role of CYP1B1 in the development and treatment of metabolic diseases","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.082073_bib27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/abio.1993.1504","article-title":"A fluorescence-based protein assay for use with a microplate reader","volume":"214","author":"Lorenzen","year":"1993","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.118.082073_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.082073_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11010-017-2943-y","article-title":"The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol","volume":"429","author":"Maayah","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/dmd.118.082073_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00204-014-1419-z","article-title":"5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-\u03baB-dependent mechanism","volume":"90","author":"Maayah","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.118.082073_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00204-015-1620-8","article-title":"The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy","volume":"90","author":"Maayah","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.118.082073_bib32","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1038\/s41598-018-20613-9","article-title":"2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy","volume":"8","author":"Maayah","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.118.082073_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1940-6207.CAPR-16-0122","article-title":"Grape seed procyanidin extract mediates antineoplastic effects against lung cancer via modulations of prostacyclin and 15-HETE eicosanoid pathways","volume":"9","author":"Mao","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1124\/dmd.118.082073_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.17219\/acem\/37123","article-title":"The role of chemokines in hypertension","volume":"23","author":"Martynowicz","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"10.1124\/dmd.118.082073_bib50","doi-asserted-by":"crossref","unstructured":"Mosli HH, Esmat A, Atawia RT, Shoieb SM, Mosli H a, Abdel-Naim AB (2015) Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective. Sci Rep 5:15639, Nature Publishing Group.","DOI":"10.1038\/srep15639"},{"key":"10.1124\/dmd.118.082073_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/13543771003602012","article-title":"5-Lipoxygenase inhibitors: a review of recent developments and patents","volume":"20","author":"Pergola","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/dmd.118.082073_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2014.03.015","article-title":"Analysis, physiological and clinical significance of 12-HETE: a neglected platelet-derived 12-lipoxygenase product","volume":"964","author":"Porro","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.082073_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbalip.2014.08.012","article-title":"5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease","volume":"1851","author":"R\u00e5dmark","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.118.082073_bib38","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1476-5381.2011.01321.x","article-title":"A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm","volume":"163","author":"Revermann","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.118.082073_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","article-title":"Molecular targets and regulators of cardiac hypertrophy","volume":"61","author":"Rohini","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.118.082073_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1124\/dmd.118.082073_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/med.10065","article-title":"Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis","volume":"24","author":"Vila","year":"2004","journal-title":"Med Res Rev"},{"key":"10.1124\/dmd.118.082073_bib42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajh\/hpu194","article-title":"Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT\/mTOR, ERK1\/2, NF-\u03baB, and calcineurin signaling pathways in mice","volume":"28","author":"Wang","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1124\/dmd.118.082073_bib43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.pharmthera.2006.05.009","article-title":"Therapeutic options for 5-lipoxygenase inhibitors","volume":"112","author":"Werz","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.082073_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-319-16009-2_6","article-title":"Cytochrome p450 enzymes in the bioactivation of polyunsaturated fatty acids and their role in cardiovascular disease","volume":"851","author":"Westphal","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/dmd.118.082073_bib45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/jpet.103.059626","article-title":"Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes","volume":"308","author":"Xu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.082073_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcp.24443","article-title":"15-LO\/15-HETE mediated vascular adventitia fibrosis via p38 MAPK-dependent TGF-\u03b2","volume":"229","author":"Zhang","year":"2014","journal-title":"J Cell Physiol"},{"key":"10.1124\/dmd.118.082073_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.freeradbiomed.2018.02.009","article-title":"CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis","volume":"117","author":"Zhou","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/dmd.118.082073_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138920008783571792","article-title":"Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure","volume":"9","author":"Zordoky","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.118.082073_bib49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2016.06.031","article-title":"Relationship between metabolites of arachidonic acid and prognosis in patients with acute coronary syndrome","volume":"144","author":"Zu","year":"2016","journal-title":"Thromb Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.082073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:37:38Z","timestamp":1739903858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624056022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0090955624056022"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.082073","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S-Enantiomer of 19-Hydroxyeicosatetraenoic Acid Preferentially Protects Against Angiotensin II-Induced Cardiac Hypertrophy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.082073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}